Friday, April 05, 2019 11:25:04 AM
AgeX Therapeutics To Present At Master Investor Show 2019
AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today that the company will participate at Master Investor Show 2019, in association with Fidelity International, on Saturday,...
By Business Wire
Apr 5, 2019 8:00 AM EDT
AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today that the company will participate at Master Investor Show 2019, in association with Fidelity International, on Saturday, April 6 in London, England. Details of the company's participation follow: Date and venueSaturday, April 6, Business Design Centre, 52 Upper Street, London 11:40-11:50am GMT - Rising Stars StageAgeX's founder and CEO, Michael D. West, Ph.D. will deliver a presentation on the company's technology and an update on its product development. 4:15-4:45pm - Panel Session: Investing in the Age of LongevityDr. West and AgeX's VP, New Technology Discovery, Aubrey de Grey, Ph.D. will serve on the panel, alongside AgeX's Chairman Gregory Bailey, M.D., who also serves as CEO of Juvenescence, a significant shareholder of AgeX. Master Investor Show is co-hosted by Jim Mellon, Chairman of Juvenescence. A copy of Dr. West's presentation will be made available on the AgeX website. About AgeX Therapeutics AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem ® and UniverCyte ™ manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX's revolutionary longevity platform named induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem ® is AgeX's delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications. For more information, please visit www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube. Forward-Looking Statements Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the "Risk Factors" section of AgeX's Annual Report on Form 10-K filed with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
Copyright Business Wire 2010
GLTA
Recent AGE News
- AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results • GlobeNewswire Inc. • 03/22/2024 09:27:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/07/2024 09:49:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:47:08 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/07/2024 12:47:43 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:01:43 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/14/2024 05:15:21 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 09:05:20 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/05/2024 12:19:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:05:39 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/17/2024 09:19:13 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 01/16/2024 02:11:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:05:36 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/09/2024 09:16:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:02:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:25:54 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/13/2023 10:11:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:05:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2023 09:05:38 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/16/2023 09:01:20 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/15/2023 02:38:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:25:21 PM
- AgeX Therapeutics Reports Third Quarter 2023 Financial Results • Business Wire • 11/14/2023 09:05:00 PM
Swifty Global Announces South African Gambling License Approval • DRCR • Jun 10, 2024 9:15 AM
DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • SONGD • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM